Vyant Bio, Inc. (VYNT) |
|
0.8049 -0.006 (-0.7%)
|
08-18 07:00 |
|
Open: |
0.81 |
Pre. Close: |
0.8106 |
|
High:
|
0.81 |
Low:
|
0.8 |
|
Volume:
|
5,788 |
Market Cap:
|
24(M) |
|
|
|
|
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.81 - 0.82 |
0.82 - 0.82 |
|
Low:
|
0.79 - 0.79 |
0.79 - 0.8 |
|
Close:
|
0.8 - 0.81 |
0.81 - 0.81 |
|
Technical analysis |
as of: 2022-08-17 4:27:44 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 0.99 One year: 1.05 |
| Support: |
Support1: 0.77 Support2: 0.64 |
| Resistance: |
Resistance1: 0.85 Resistance2: 0.89 |
| Pivot: |
0.82 |
| Moving Average: |
MA(5): 0.81  MA(20): 0.83
MA(100): 0.87 MA(250): 1.4 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 34.4 %D(3): 36.9 |
| RSI: |
RSI(14): 44.9 |
| 52-week: |
High: 3.24 Low: 0.6 |
| Average Vol(K): |
3-Month: 98 (K) 10-Days: 38 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VYNT ] has closed above bottom band by 28.2%. Bollinger Bands are 74.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 29 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Wed, 17 Aug 2022
Vyant Bio, Inc. (NASDAQ: VYNT) Featured in Coverage of Investor Summit Group's Q3 Virtual Event - StreetInsider.com
Sat, 13 Aug 2022
Vyant Bio (VYNT) to Release Quarterly Earnings on Monday - Defense World
Tue, 09 Aug 2022
Immatics (IMTX) Reports Q2 Loss, Lags Revenue Estimates - Nasdaq
Wed, 03 Aug 2022
Vyant Bio to Present at Investor Summit Group's Q3 Virtual Conference - Yahoo Finance
Wed, 20 Jul 2022
Vyant Bio (NASDAQ: VYNT) Engages Skyline Corporate Communications Group, LLC To Continue Advancing Its Co - Benzinga
Wed, 01 Jun 2022
Vyant Bio Retains Skyline Corporate Communications Group, LLC to Provide Investor Relations Services - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
29 (M) |
|
% Held by Insiders
|
2.361e+007 (%) |
|
% Held by Institutions
|
24.8 (%) |
|
Shares Short
|
357 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.45e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
207.1 |
|
Return on Equity (ttm)
|
-18 |
|
Qtrly Rev. Growth
|
1.25e+006 |
|
Gross Profit (p.s.)
|
-0.01 |
|
Sales Per Share
|
0.13 |
|
EBITDA (p.s.)
|
-0.39 |
|
Qtrly Earnings Growth
|
1.2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-16 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0 |
|
Price to Sales
|
5.92 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
144060 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-10-24 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
